Proactive Investors - Run By Investors For Investors

Cellmid board members hoover up company stock

Non-executive director Dennis Eck purchased $1 million worth of stock for 38 cents.
board room table surrounded by empty chairs
The board purchases show their confidence in the company's future

Cellmid Ltd (ASX:CDY) has had four of its board members purchase company stock recently with one member buying $1 million worth of shares.

The share purchases were made in a variety of ways including on-market trades and participation in the recent share placement and share purchase plan (SPP).

The board members that increased their holdings were managing director and CEO Maria Halasz and non-executive directors Bruce Gordon, Dr Martin Cross and Dennis Eck.

Eck acquired 2.63 million shares for $1 million, Halasz acquired 263,157 for $100,000, Dr Cross acquired 130,000 shares for $50,400, and Gordon acquired 26,316 shares for $10,000.

READ: Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

 

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
1538160791_petri-dishes.jpg
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use